

Barcelona, 16th December 2016

SIGNIFICANT EVENT

Almirall: Receipt of 30 million dollars related to milestones from the agreement with AstraZeneca

Almirall, S.A. (ALM.MC), as per section 228 of the Royal Legislative Decree 4/2015, of 23 October 2015, approving the Restated Text of the Securities Market Act, hereby announces that:

Today, 16th December 2016, a payment of 30 million dollars has been received associated with the agreement signed with AstraZeneca, on 1 November 2014 and relating to a sales milestone for acclidinium bromide franchise, as a Bronchodilator treatment to relieve the symptoms of chronic obstructive pulmonary disease (COPD).

Additionally, Phase III studies for the registration of acclidinium + formoterol combination in US are progressing as scheduled and we remain positive about this partnership and associated potential future milestones.

Sincerely,

Pablo Divasson del Fraile
Investor Relations and Corporate Communications Department
inversores@almirall.com

